>>>welcome visitor, haven't logged in. Login
Subscribe Now Contact us  
Font Size:  A A A Search “Fabao” Window English 中文 = 简体  繁体
  Favorite   DownLoad   Print
 
Announcement No. 92 [2017] of the Ministry of Commerce—Announcement on Decision from Anti-Monopoly Review of the Concentration of Undertakings on Conditional Approval of Proposed Merger between Becton, Dickinson and Company and C. R. Bard, Inc. [Effective]
商务部公告2017年第92号――关于附加限制性条件批准贝克顿-迪金森公司与美国巴德公司合并案经营者集中反垄断审查决定的公告 [现行有效]
【法宝引证码】

Announcement of the Ministry of Commerce 

商务部公告

(No. 92 [2017]) (2017年第92号)

Announcement on Decisions from Anti-Monopoly Review of the Concentration of Undertakings on Conditional Approval of Proposed Merger between Becton, Dickinson and Company and C. R. Bard, Inc. 关于附加限制性条件批准贝克顿-迪金森公司与美国巴德公司合并案经营者集中反垄断审查决定的公告
The Ministry of Commerce of the People's Republic of China (hereinafter referred to as the "MOFCOM") received the anti-monopoly declaration of the concentration of undertakings on the case of merger between Becton, Dickinson and Company (hereinafter referred to as the "Becton") and C. R. Bard, Inc. (hereinafter referred to as the "Bard") (hereinafter referred to as the "Case"). Upon review, the MOFCOM decided to conditionally approve the concentration of undertakings. In accordance with Article 30 of the Anti-Monopoly Law of the People's Republic of China (hereinafter referred to as the "Anti-Monopoly Law"), relevant matters are hereby announced as follows: 中华人民共和国商务部(以下简称商务部)收到贝克顿-迪金森公司(Becton, Dickinson and Company,以下简称贝克顿)与美国巴德公司(C. R. Bard, Inc.,以下简称巴德)合并案(以下简称本案)的经营者集中反垄断申报。经审查,商务部决定附加限制性条件批准此项经营者集中。根据《中华人民共和国反垄断法》(以下简称《反垄断法》)第三十条,现公告如下:
I. Case-filing and review procedures   一、立案和审查程序
On June 20, 2017, the MOFCOM received the anti-monopoly declaration for the concentration of undertakings concerning the Case. Upon review, the MOFCOM considered that the documents for declaration were incomplete, and required the declarers (including Becton and Bard, the same below) to make supplements. On July 12, the MOFCOM confirmed that the materials so supplemented complied with Article 23 of the Anti-Monopoly Law, and therefore granted case filing for the anti-monopoly declaration for the concentration of undertakings to commence the preliminary examination. On August 10, 2017, the MOFCOM decided to further examine this concentration of undertakings. Upon further examination, the MOFCOM considered that the concentration might have the effects of excluding or restricting competition in the core biopsy device market in China. On November 6, with the consent of the declarers, the MOFCOM decided to extend the period for the further examination to January 4, 2018. 2017年6月20日,商务部收到本案的经营者集中反垄断申报。经审核,商务部认为该申报材料不完备,要求申报方(包括贝克顿和巴德,下同)予以补充。7月12日,商务部确认经补充的申报材料符合《反垄断法》二十三条规定,对此项经营者集中申报予以立案并开始初步审查。2017年8月10日,商务部决定对此项经营者集中实施进一步审查。经进一步审查,商务部认为此项集中对中国粗针穿刺活体组织检查器械市场可能具有排除、限制竞争的效果。11月6日,经申报方同意,商务部决定延长进一步审查期限,进一步审查延长阶段截止日期为2018年1月4日。
In the course of the examination, the MOFCOM requested opinions from relevant government agencies, industry associations, downstream customers, industry experts, and clinicians, convened seminars to gather information in the definition of relevant markets, market competition structure, industry characteristics, and other aspects, and reviewed the authenticity, integrity, and accuracy of the documents and materials submitted by the declarers. 在审查过程中,商务部征求了有关政府部门、行业协会、下游客户、行业专家及临床医生意见,多次召开座谈会了解相关市场界定、市场竞争结构、行业特征等方面信息,并对申报方提交的文件、材料的真实性、完整性和准确性进行了审核。
II. Basic information of the Case   二、案件基本情况
Becton, a party to the merger, is a company established in the United States in 1906 and listed on the New York Stock Exchange. Becton offers medical devices and medical solutions worldwide and in China. 合并一方贝克顿于1906年在美国设立,是纽约证券交易所上市公司。贝克顿在全球及中国提供医疗器械及医学解决方案。
Bard, the other party to the merger, is a company established in the United States in 1923 and listed on the New York Stock Exchange and Deutsche B?rse. Bard is engaged in the design, manufacture and sale of medical diagnostic and patient care equipment worldwide and in China. 合并另一方巴德于1923年在美国设立,是纽约和德意志证券交易所上市公司。巴德在全球及中国从事医疗诊断和病人护理设备的设计、生产和销售业务。
The transaction will enable Bard to exploit Becton's broader global geographic presence to achieve the complementation of the products of both parties to the transaction and create new market development opportunities. 本交易将使巴德能够利用贝克顿更广阔的全球地域布局,实现交易双方产品互补,创造新的市场发展机遇。
III. Related markets   三、相关市场
1. Goods market. (一)相关商品市场。
As examined, the declarers horizontally overlap each other in the core biopsy device market in China. 经审查,申报方在中国粗针穿刺活体组织检查器械市场存在横向重叠。
Biopsy devices can be divided into soft tissue biopsy devices and bone marrow biopsy devices. A bone marrow biopsy device is used to penetrate bone to collect liquid bone marrow tissue or solid bone marrow. In view of factors, such as shape, characteristics, use, and prices, bone marrow biopsy devices have no close substitution relationship with soft tissue biopsy devices, and they belong to independent relevant goods markets. 活体组织检查(以下简称活检)器械可分为软组织活检器械和骨髓活检器械,骨髓活检器械需要探入骨质提取液体骨髓组织或固体骨髓块,从外形、特性、用途和价格等因素分析,骨髓活检器械与软组织活检器械之间不具有较为紧密的替代关系,分别构成独立的相关商品市场。
Soft tissue biopsy devices mainly include core biopsy devices, fine aspiration biopsy devices and vacuum-assisted biopsy devices. A core biopsy device consists of a handle and a disposable needle, which penetrates the body of a patient to remove and obtain a cylindrical tissue sample. A fine aspiration biopsy device consists of a syringe, open-end cannula, and a disposable stylet, which penetrates the body of a patient to collect body fluid and other cell samples. A vacuum-assisted biopsy device consists of a biopsy driver, a tissue collection chamber, and a larger-sized probe, and can collect more than one tissue samples from certain locations in the same procedure. From the perspective of demand substitution, the three types of biopsy devices differ significantly in function, use, applicable field, and average price, among others. From the perspective of supply substitution, it takes expensive costs and long time for manufacturers to make a shift from one of the three types to another. Becton and Bard, the parties to the transaction, horizontally overlap each other only in the core biopsy device market in China. Therefore, the relevant goods market is defined as the core biopsy device market.
......
 软组织活检器械主要包括粗针穿刺活检器械、细针抽吸活检器械和真空辅助活检器械三类。粗针穿刺活检器械由粗针枪柄及一次性针具组成,针具插入病人体内切除并取出圆柱状组织样本。细针抽吸活检器械由注射器、开放式导管和更细的一次性针具组成,针具插入病人体内提取体液等细胞样本。真空辅助活检器械由旋切装置、真空取样腔和尺寸较大的探针组成,可以在同一过程中从多个位置提取多个组织样本。从需求替代角度分析,上述三种软组织活检器械的功能、用途、适用领域、平均价格等存在显著差异。从供给替代角度分析,厂商在上述三种器械之间转换面临较高的转产成本和较长的转产时间。交易方贝克顿和巴德仅在中国粗针穿刺活检器械市场存在横向重叠,因此,相关商品市场界定为粗针穿刺活检器械市场。
......

Dear visitor, as a premium member of this database, you will get complete access to all content.Please go premium and get more.

1. To become a premium member, please call 400-810-8266 Ext. 171.

2. Binding to the account with access to this database.

3. Apply for a trial account.

4. To get instant access to a document, you can Pay Amount 【¥400.00】 for your single purchase.
 
您好:您现在要进入的是北大法宝英文库会员专区。
如您是我们英文用户可直接 登录,进入会员专区查询您所需要的信息;如您还不是我们 的英文用户;您可通过网上支付进行单篇购买,支付成功后即可立即查看本篇内容。
Tel: +86 (10) 82689699, +86 (10) 82668266 ext. 153
Mobile: +86 13311570713
Fax: +86 (10) 82668268
E-mail:info@chinalawinfo.com
     
     
Scan QR Code and Read on Mobile
【法宝引证码】        北大法宝en.pkulaw.cn
Message: Please kindly comment on the present translation.
 
Confirmation Code:
Click image to reset code
 
  Translations are by lawinfochina.com, and we retain exclusive copyright over content found on our website except for content we publish as authorized by respective copyright owners or content that is publicly available from government sources.

Due to differences in language, legal systems, and culture, English translations of Chinese law are for reference purposes only. Please use the official Chinese-language versions as the final authority. Lawinfochina.com and its staff will not be directly or indirectly liable for use of materials found on this website.

We welcome your comments and suggestions, which assist us in continuing to improve the quality of our materials as we dynamically expand content.
 
Home | About us | Disclaimer | Chinese